Navigation Links
Preferable treatment for MS found in allogenic bone marrow stem cells
Date:12/18/2013

Putnam Valley, NY. (Dec. 18, 2013) Multiple sclerosis (MS), an inflammatory autoimmune disease affecting more than one million people worldwide, is caused by an immune reaction to myelin proteins, the proteins that help form the myelin insulating substance around nerves. Demyelination and MS are a consequence of this immune reaction. Bone marrow mesenchymal stem cells (MSCs) have been considered as an important source for cell therapy for autoimmune diseases such as MS because of their immunosuppressive properties.

Now, a research team in Brazil has compared MSCs isolated from MS patients and from healthy donors to determine if the MSCs from MS patients are normal or defective. The study will be published in a future issue of Cell Transplantation but is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1131.

"The ability of MSCs to modulate the immune response suggests a possible role of these cells in tolerance induction in patients with autoimmune diseases, and also supports the rationale for MSC application in the treatment of MS," said study corresponding author Dr. Gislane Lelis Vilela de Oliveira of the Center for Cell-Based Research at the University of Sao Paulo. "We found that MS patient-derived MSCs present higher senescence, or biological aging, and decreased expression of important immune system markers as well as a different transcriptional profile when compared to their healthy counterparts."

The researchers suggested that further clinical studies should be conducted using transplanted allogenic (other-donated) MSCs derived from healthy donors to determine if the MSCs have a therapeutic effect over transplanted autologous (self-donated) MSCs from patients.

"Several reports have shown that bone marrow-derived MSCs are able to modulate innate and adaptive immunity cell responses and induce tolerance, thus supporting the rationale for their application in treating autoimmune diseases, " said the researchers.

They also noted that studies have shown that transplanted MSCs migrate to demyelinated areas as well as induce generation and expansion of regulatory T cells, important in immunity.

"We found that the transcriptional profile of patient MSCs after transplantation was closer to that of their pre-transplant MSC samples than those from their healthy counterparts, suggesting that treatment with patient self-donated MSCs does not reverse the alterations we observed in MSCs from MS patients," they concluded.

The researchers further noted that their results might not be representative of "typical" MS patients because their study included only patients who were refractory to conventional treatments.

"This study highlights one of the potential problems with autologous stem cell transplants" said Dr. Paul R. Sanberg, distinguished professor at the Center of Excellence for Aging and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL. "Autologous cells are frequently affected by the disease etiology thus reducing their ability to be effective, meaning that allogenic transplants maybe preferable to maximize their potential benefit if other concerns such as rejection can be overcome."


'/>"/>

Contact: Robert Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Packaging insulin into a pill-friendly form for diabetes treatment
2. Physicians awarded $4 million to study effects of fertility treatments and obstetric care
3. U-M tinnitus discovery opens door to possible new treatment avenues
4. Wayne State discovers potential treatment for skin and corneal wound healing in diabetics
5. New gene therapy proves promising as hemophilia treatment
6. Picturing pain could help unlock its mysteries and lead to better treatments
7. Scientists identified T372R mutation as potential target for diagnosis and treatment of insulinoma
8. Targeted treatment can significantly reduce relapse in children with AML leukemia
9. Columbias 2013 Horwitz Prize awarded for discoveries that could lead to new Alzheimers treatments
10. MassBiologics receives orphan drug status from FDA for hepatitis C treatment
11. New compound for slowing the aging process can lead to novel treatments for brain diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
Breaking Biology News(10 mins):
(Date:6/22/2016)...  According to Kalorama Information, the dominant trends ... include significant efforts in automation as well as ... affordable sequencers, say the healthcare market research firm, ... sample prep materials.  The healthcare market research company,s ... Next Generation Sequencing (NGS) , highlights major trends ...
(Date:6/22/2016)... DIEGO , June 22, 2016   ViaCyte, ... first pluripotent stem cell-derived islet replacement therapy for the ... presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, the ... to 25th at Moscone West in San Francisco.  ... of the presentations are as follows:Event: , Focus Session: ...
(Date:6/22/2016)... 22, 2016  Mesa Biotech Inc., a privately-held, ... platform designed specifically for point-of-care (POC) infectious disease ... advisory board (SAB). Approved by the executive leadership ... chartered to advise on the development and commercialization ... by Dr. Steve Young , this world-class ...
(Date:6/21/2016)... , June 22, 2016 Frontier Biotechnologies Inc. ... its novel patch product AB001 met primary endpoint at ... relief against placebo. Conducted at nine clinical centers in ... enrolled 146 patients with chronic low back pain. AB001 ... week-1 (p=0.024), (2) greater reduction than placebo in the ...
Breaking Biology Technology: